Sign In To Continue
You have reached the guest article limit.
Unlock more of the IIPLA newsroom by signing in with SSO or joining as a member.
The underlying dispute centers on Novartis' U.S. Patent No. 8,101,659, which covers the use of sacubitril/valsartan (sold under the brand name Entresto) for treating heart failure with reduced ejection fraction (HFrEF...
Share This Article
Ready-to-post copy includes the article link.
Patent Showdown: Federal Circuit Freezes MSN’s Entresto Launch Amid Novartis Battle The underlying dispute centers on Novartis' U.S. Patent No. 8,101,659, which covers the use of sacubitril/valsartan (sold under the brand name Entresto) for treating heart failure with reduced ejection fraction (HFrEF... Read the full IIPLA article: https://iipla.org/news/federal-court-halts-entresto-generic